FDA Issues Class II Recall for Chlorthalidone Tablets

The U.S. Food and Drug Administration (FDA) has announced a second nationwide recall of chlorthalidone blood pressure tablets, classifying it as a Class II recall. This action follows the failure of over 13,000 bottles to meet dissolution testing standards.

Potential Risks of Ineffective Medication

The recalled chlorthalidone tablets may not dissolve properly in the body, which could hinder patients’ absorption of the active ingredient, ultimately reducing the medication’s effectiveness in managing blood pressure.

Details of the Recall

Initiated by Inventia Healthcare Limited of India on September 3, the FDA confirmed the Class II classification on September 17. The recall affects a total of 13,567 bottles of Chlorthalidone Tablets, USP, 25 mg, distributed across the United States.

Understanding Class II Recall

The FDA’s Class II designation indicates that the use of the affected product could lead to temporary or medically reversible adverse health effects. However, the agency assesses the likelihood of serious harm as minimal.

Importance of Dissolution Testing

Dissolution testing is crucial as it evaluates how quickly and effectively a medication releases its active ingredient for absorption in the body. A tablet may appear normal but fail to perform adequately, which can result in less effective treatment for patients relying on chlorthalidone.

Previous Recall

This is not the first incident involving chlorthalidone from Inventia. In June 2023, the company recalled 11,460 bottles of the same medication in 100-tablet and 1,000-tablet sizes for similar dissolution testing failures, also classified as Class II by the FDA.

Health Implications for Patients

Chlorthalidone is a diuretic, commonly known as a “water pill,” that assists the kidneys in eliminating excess water and salt, thereby lowering blood pressure. Reduced efficacy of this medication can lead to poorly controlled hypertension, increasing the long-term risk of severe complications such as heart attack, stroke, and kidney damage.

Patient Guidance

Patients who suspect they have the recalled chlorthalidone should not stop taking the medication abruptly without consulting their healthcare provider. Discontinuing blood pressure medication suddenly can pose health risks, making medical guidance essential. Individuals experiencing any adverse symptoms or changes in their condition should seek medical attention promptly.

As the FDA’s second recall of chlorthalidone unfolds, both patients and healthcare professionals are urged to remain vigilant regarding the affected products and to discuss any necessary medication changes with medical experts.

Source Reference (usaherald.com): FDA Chlorthalidone Dissolution Testing Recall Hits More Than 13,000 Bottles Nationwide